UPDATE: Wedbush Raises PT on Endocyte on Significant Catalysts Ahead
March 27, 2013 at 12:14 PM EDT
In a report published Wednesday, Wedbush analyst Gregory R. Wade reiterated an Outperform rating on Endocyte (NASDAQ: ECYT ), and raised the price target from $16.00 to $20.00. In the report, Wade noted, “Endocyte is developing novel drug candidates based on its small molecule drug conjugate technology and companion imaging
